创模生物科技(北京)有限公司

CN / En

NEWS

Technical characteristics of in vitro high throughput drug screening service for PDC model

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2021-01-27 15:35
  • Views:

(Summary description)High-throughput screening of chemotherapeutic, targeted, and immune checkpoint drugs; Ten standardised treatment guideline drugs can be screened when using a patient's tumor Using PDX model, up to 60 kinds of chemotherapy and targeted drugs can be screened In vitro use of patient PBMC co-culture, immune checkpoint drug efficacy can be verified. 10 working days to provide testing report, strong timeliness; The experimental process is simple and quick, and has little effect on the activity of tumor cells. The success rate of the experiment is 100% after obtaining enough tumor cells from patients. It can provide effective reference for the follow-up efficacy evaluation and clinical treatment in vivo.

Technical characteristics of in vitro high throughput drug screening service for PDC model

(Summary description)High-throughput screening of chemotherapeutic, targeted, and immune checkpoint drugs;

Ten standardised treatment guideline drugs can be screened when using a patient's tumor

Using PDX model, up to 60 kinds of chemotherapy and targeted drugs can be screened

In vitro use of patient PBMC co-culture, immune checkpoint drug efficacy can be verified.

10 working days to provide testing report, strong timeliness;

The experimental process is simple and quick, and has little effect on the activity of tumor cells. The success rate of the experiment is 100% after obtaining enough tumor cells from patients.

It can provide effective reference for the follow-up efficacy evaluation and clinical treatment in vivo.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2021-01-27 15:35
  • Views:
Information

High-throughput screening of chemotherapeutic, targeted, and immune checkpoint drugs;

Ten standardised treatment guideline drugs can be screened when using a patient's tumor

Using PDX model, up to 60 kinds of chemotherapy and targeted drugs can be screened

In vitro use of patient PBMC co-culture, immune checkpoint drug efficacy can be verified.

10 working days to provide testing report, strong timeliness;

The experimental process is simple and quick, and has little effect on the activity of tumor cells. The success rate of the experiment is 100% after obtaining enough tumor cells from patients.

It can provide effective reference for the follow-up efficacy evaluation and clinical treatment in vivo.

In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
In the vast field of cancer research and drug development, InnoModels Biotechnology (Beijing) Co., Ltd. provides powerful support to scientists and doctors with its leading CDX (Cell line-derived xenograft tumor) model platform. The platform not only has diverse tumor cell lines, but also is equipped with a team of experienced experts and advanced experimental technologies, which are dedicated to promoting innovation in biomedical research and clinical treatment.
In the field of life sciences, in vitro killing experimental platform is gradually becoming an important tool for drug development and cell research. Among them, the in vitro killing experimental platform of InnoModels Biotechnology has attracted the attention of many researchers with its unique technical advantages and wide application prospects. In this paper, we will introduce in detail the features and advantages of InnoModels' in vitro killing platform and its applications in scientific research.
In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is leading the forefront of tumor and tumor immunotherapy research with its unique in vivo tumor experimental platform, which is like a bright star. The platform not only integrates the most advanced technologies and experimental methods, but also devotes itself to providing a new generation of experimental animal models close to the clinic
In the vast field of life science and drug discovery, in vitro experimental platforms play a crucial role. As a leader in this field, InnoModels Biotechnology (Beijing) Co., Ltd. provides scientists with a highly controlled and precise experimental environment with its in vitro killing platform, which greatly facilitates the screening of new drugs, the study of drug mechanisms, and the development of immunotherapies.
In the broad field of tumor research and new drug development for tumor immunotherapy, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully launched a high mesenchymal tumor transplantation model by virtue of its profound accumulation and technological innovation in the field of model construction, which provides strong support for tumor research and drug development. In this article, we will introduce in detail how InnoModels Biotechnology has made a breakthrough in this field, and explain the importance of high mesenchymal tumor models and their application prospects.
Previous page
1
2
42

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司